Compare SXT & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXT | LGND |
|---|---|---|
| Founded | 1882 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | SXT | LGND |
|---|---|---|
| Price | $94.46 | $189.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $110.00 | ★ $239.33 |
| AVG Volume (30 Days) | ★ 293.4K | 212.6K |
| Earning Date | 02-13-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 56.32 | 0.76 |
| EPS | ★ 3.27 | 2.49 |
| Revenue | ★ $1,595,084,000.00 | $251,233,000.00 |
| Revenue This Year | $4.80 | $52.87 |
| Revenue Next Year | $5.94 | $6.07 |
| P/E Ratio | ★ $29.13 | $78.37 |
| Revenue Growth | 4.25 | ★ 64.83 |
| 52 Week Low | $66.15 | $93.58 |
| 52 Week High | $121.54 | $212.49 |
| Indicator | SXT | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 42.70 |
| Support Level | $92.50 | $194.44 |
| Resistance Level | $96.75 | $198.80 |
| Average True Range (ATR) | 2.18 | 5.59 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 45.43 | 42.58 |
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are; Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.